How did NKTX's operating expenses trend in Q4 2024?

NKTX's operating expenses for Q4 2024 are not currently available. However, the latest available data is from Q3 2024, where the company reported $33.8 million in operating expenses. This includes $25.3 million in research and development expenses and $8.5 million in general and administrative expenses.

Given that NKTX continued its clinical trials and development initiatives in Q4 2024, as evidenced by the IND clearance for an investigator-sponsored trial in myasthenia gravis and the opening of enrollment for Ntrust-2, it is reasonable to assume that operating expenses may have been comparable to or slightly higher than Q3 2024.

The company's focus on advancing its NKX019 therapy for multiple autoimmune diseases and the ongoing enrollment in clinical trials suggest that NKTX may have maintained its spending trajectory in Q4 2024 to support these critical development activities.